Keiki Nagaharu
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Prospective next-generation sequence analysis of genetic mutations in myeloproliferative neoplasms
Open Date: 2022-04-01
Close Date: 2024-04-01
Grant: Close
Novel Lymphoid Pathway of Human Plasmacytoid Dendritic cells
Open Date: 2019-09-01
Close Date: 2020-09-01
Grant: Close
a novel relationship between human B and pDC differentiation
Open Date: 2019-03-01
Close Date: 2021-03-01
Grant: Close
Exploring lineage determining factors for human megakaryocytes or erythroid differentiation in patients with JAK2 V617F by a novel fluctuation-based methodology
Open Date:
Close Date:
Articles (17)
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Congenital vascular malformations, affecting 0.5% of the population, often occur in the head and neck, complicating treatment due to the critical functions in these regions. Our previous research identified distinct developmental origins for blood and lymphatic vessels in these areas, tracing them to the cardiopharyngeal mesoderm (CPM), which contributes to the development of the head, neck, and cardiovascular system in both mouse and human embryos. In this study, we investigated the pathogenesis of these malformations by expressing Pik3ca H1047R in the CPM. Mice expressing Pik3ca H1047R in the CPM developed vascular abnormalities restricted to the head and neck. Single-cell RNA sequencing revealed that Pik3ca H1047R upregulates Vegf-a expression in endothelial cells through HIF-mediated hypoxia signaling. Human samples supported these findings, showing elevated HIF-1α and VEGF-A in malformed vessels. Notably, inhibition of HIF-1α and VEGF-A in the mouse model significantly reduced abnormal vasculature. These results highlight the role of embryonic origins and hypoxia-driven mechanisms in vascular malformations, providing a foundation for the development of therapies targeting these difficult-to-treat conditions.
Year:
2025
Year:
2025
Background Recent progress of engineered T cells genetically modified to express tumor-specific T-cell receptors (TCR-T) has demonstrated promising perspectives for treatment of a variety of cancers. Nonetheless, the efficacy of this strategy against solid tumors is still unsatisfactory due to poor expansion, loss of function, and short persistence of the infused cells in vivo. To overcome this, different combination therapies with other modalities, including cancer vaccines and immune-checkpoint inhibitors (ICIs), have attracted attention and are currently being developed to achieve long-term patients' survival. However, the optimal strategy has not been determined yet. Recently, we newly developed a novel cancer vaccine based on hyaluronic acid nanogel (HANG-Vax). HANG can easily embed various substances, such as long peptides, leading to form nanoparticles of about 100 nano meter diameter. HANG-Vax can efficiently deliver vaccine antigens to antigen presenting cells present in lymph nodes after subcutaneous injection. Aims In this study, we investigated the efficacy of the combined treatment of HANG-Vax with TCR-T therapy by using tumor-bearing mouse models. Methods The efficacy of the combination of TCR-T and HANG-Vax therapy was examined by using each tumor bearing mouse treatment model. Here, we utilized C57BL/6-derived B16F10 melanoma cell line, which is resistant to ICIs and TCR-T therapies. TCR-T cells were prepared from splenic CD8+ T cells of Pmel-1 mice transfected with TCR that specifically recognize gp100. HANG-Vax was prepared by mixing HANG with long peptide encoding gp100. HANG-Vax was subcutaneously injected on day 7, 11 and 15, and CD8+ T cells were intravenously administered on day 8 and 12 after tumor inoculation. Along with monitoring tumor growth, single-cell RNA/TCR seq analysis and spatial gene expression analysis were performed to analyze the dynamics of the infused TCR-T cells in lymph nodes and tumor tissues. Results Malignant cell transplantation revealed that complete eradication of B16F10 tumors was observed in all mice treated with TCR-T and HANG-Vax therapy. In contrast, the other groups of mice were all dead until 25 days after transplantation of B16F10. Mice that achieved complete remission (CR) survived for long periods and exhibited vitiligo hair. Single-cell RNA/TCR seq analysis of the lymph nodes from each group revealed that HANG-Vax induced the clonal expansion of TCR-T, but much less in TCR-T monotherapy. Projection of reference data identified that HANG-Vax differentiated the TCR-T toward effector memory T cells. In addition, the differential gene expression analysis across the groups showed that HANG-Vax treatment induced the expression of cytotoxic genes such as Granzyme B. KEGG-pathway analysis using the differentially expressed genes highlighted the HANG-Vax accelerated not only “cell-killing”-related gene expression but also “cell metabolism/proliferation”-related genes. These suggested the clonal survival and expansion was induced in HANG-Vax. To confirm the efficient recruitment of cytotoxic T cells at the tumor site, further analysis utilizing the spatial expression analysis was performed. CD8+T cells were highly co-exisiting with Pmel expressing tumor cells in HANG-Vax treatment group. Pseudo-bulk analysis of these spatial expression data showed significantly higher levels of “cytotoxicity” and “positive activation of immune cell”-related genes. Regarding the non-T population of tumor site, we performed deconvolutional analysis of each spot using Deepcolor method. Interestingly, TCR-T with HANG-Vax induced the higher expression of chemokines, including Ccl4, Ccl5, Cxcl9, and identified that HANG-Vax treatment group possessed higher macrophage invasion with M1 macrophage, suggesting HANG system empowered the macrophage-related anti-neoplastic effect in addition to CD8+ T cell cytotoxicity. Summary/Conclusion These results indicate that HANG-Vax can potently maximize the effica
Year:
2025
Year:
2025
BACKGROUND Acute myocarditis is an immune-mediated inflammatory disease characterized by myocardial inflammation and edema. Cardiac lymphatic vessels are essential for fluid clearance and immune regulation; however, their role in modulating inflammation in autoimmune myocarditis remains largely unclear. METHODS We investigated the impact of cardiac lymphangiogenesis using a murine model of experimental autoimmune myocarditis induced by cardiac myosin peptide immunization. Human autopsy samples were analyzed for lymphatic expansion. Mice were treated with VEGF-C C156S, a VEGFR3-specific agonist, beginning one week after immunization. Cardiac lymphangiogenesis, myocardial edema, inflammatory infiltration, fibrosis, and cardiac function were evaluated by immunohistochemistry, echocardiography, gene expression analysis, and water content measurements. RESULTS The VEGF-C treatment accelerated cardiac lymphangiogenesis, enhanced lymphatic drainage, reduced myocardial edema, and attenuated inflammatory cell infiltration and fibrosis. Echocardiography showed the preservation of left ventricular function. VEGF-C selectively decreased the accumulation of iNOS⁺ inflammatory macrophages without broadly suppressing T cells or reparative macrophages. Bulk RNA sequencing confirmed the down-regulation of inflammatory gene signatures associated with macrophage activation. CONCLUSIONS The early stimulation of cardiac lymphangiogenesis by VEGF-C promotes the resolution of inflammation, reduces myocardial injury, and preserves cardiac function in autoimmune myocarditis. Targeting the cardiac lymphatic system may represent a promising therapeutic strategy for acute myocarditis.
Year:
2025
Background . Autoimmune hemolytic anemia (AIHA) associated with solid tumors such as mature cystic teratomas is rare and poorly understood. Here, we report a successfully treated case of secondary AIHA in a mature cystic teratoma containing antibodies against red blood cells. Case description . A 22-year-old woman was referred to our hospital with progressive anemia. Laboratory findings revealed hemolysis with a positive direct and indirect antiglobulin test. Imaging studies identified a left ovarian mass, suspected to be a mature cystic teratoma, which was later confirmed by histopathology after laparoscopic oophorocystectomy. The patient was treated with prednisolone, resulting in improved anemia. To examine the relationship between the tumor and AIHA, an indirect antiglobulin test was performed on the tumor contents. Stronger aggregations were observed at any concentration diluted by 10 times from 10 to 10,000 times of the tumor contents compared to the patient’s serum. Additionally, immunofixation electrophoresis of the tumor contents revealed the presence of monoclonal immunoglobulin G- κ . Conclusion . The presence of monoclonal IgG- κ in the tumor suggests intratumoral antibody production as a possible mechanism. Further research is necessary to elucidate the pathogenic relationship between such tumors and AIHA. The report also highlights the importance of considering secondary AIHA in patients with unexplained anemia and solid tumors.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (9)
Kaoru Dohi
Mie University Graduate School of Medicine
Tetsuya Nosaka
Professor
Mie university
Yuma Nato
Mie University Graduate School of Medicine
Kazuaki Maruyama
Assistant Professor
Mie University Graduate School of Medicine
Yuka Sugimoto
Associate professor
Mie university
Isao Tawara
-
Charlotta Böiers
Lund University
Kohshi Ohishi
Mie University Hospital
Eiichi Morii
Professor
Osaka University
Make your next move.
Prepare your application
Review drafts before you send them.